FDA adcomm returns mixed vote on GSK’s CKD drug FDA/Regulatory, R&D An FDA adcomm that met Wednesday to vote on GlaxoSmithKline’s daprodustat for adult patients with anemia due to chronic kidney disease (CKD) produced mixed results. Read more October 27, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/05/US-Bridging-Study-Not-Enough-as-FDA-Denies-Hutchmeds-Pancreatic-Cancer-Drug-BioSpace-5-2-22.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-10-27 11:22:012022-10-27 11:22:01FDA adcomm returns mixed vote on GSK’s CKD drug
